Mallinckrodt Q1 Acthar Gel sales down 25%

Mallinckrodt (MNK) Q1 results:

Revenues: $665.8M (-15.8%); Acthar Gel: $167.6M (-25.1%); INOmax: $141.7M (-6.2%); Ofirmev: $74.9M (-21.7%).

Net loss: ($56.7M) (-136.5%); loss/share: ($0.67) (-136.6%); non-GAAP Net Income: $138.3M (-15.9%); non-GAAP EPS: $1.64 (-15.5%).

CF Ops: $53.7M (-67.4%).

Previously: Mallinckrodt EPS beats by $0.21, misses on revenue (May 5)

https://seekingalpha.com/news/3568983-mallinckrodt-q1-acthar-gel-sales-down-25